Search Results - Application+%3e+Therapeutics

773 Results

Sort By:

Humanized Monoclonal Antibodies Specific Against Human Soluble Tissue Factor (hsTF) as Diagnosis, Prevention and Therapeutic Agents for Thrombosis

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a novel humanized monoclonal antibody (58B3) that selectively targets a newly identified soluble Tissue Factor (sTF) to diagnose, prevent and treat pathological thrombosis associated with inflammation, viral/bacterial infection, sepsis and cancer...

Published: 9/29/2025 | Inventor(s): Zheng-gang Liu, Swati Choksi, PeiXing Wan

Keywords(s):

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology, Application > Diagnostics, Application > Therapeutics

Combination PDL1 and TGF Beta Blockade in Patients with HPV-Associated Malignancies

Summary: The National Cancer Institute (NCI) seeks collaborations and licensees for a method to block PD-L1 and TGF-beta for the treatment of HPV-associated malignancies. Description of Technology: Advanced or relapsed human papillomavirus (HPV)-associated cancers are incurable and many of these diseases do not have a standard second line therapy....

Published: 11/26/2025 | Inventor(s): Julius Strauss, James Gulley, Christian Hinrichs

Keywords(s):

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Oncology

Identification and Characterization of HLA-A24 Agonist Epitopes of MUC1 Oncoprotein

Summary: The National Cancer Institute (NCI) seeks co-development partners and licensees for a human cytotoxic T lymphocyte agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), in a cancer vaccine or T-cell targeted therapy to target many tumor types. Description of Technology: Many...

Published: 9/29/2025 | Inventor(s): Jeffrey Schlom, Kwong-Yok Tsang

Keywords(s):

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Oncology

Innovative Antibody Conjugation Technology for Therapeutic and Diagnostic Applications

This pioneering technology introduces a novel method for conjugating antibodies, designed to dramatically enhance their therapeutic and diagnostic performance. By improving both binding efficiency and target specificity, this approach overcomes critical limitations of existing antibody-based therapies and imaging tools. The result is a versatile platform...

Published: 1/2/2026 | Inventor(s): Parinaz Fathi, Frank Borris, Kaitlyn Sadtler

Keywords(s):

Category(s): Application, Application > Therapeutics, Application > Diagnostics, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease

Advanced Biodegradable Polymers for Medical Devices

This breakthrough technology features advanced biodegradable polymers engineered specifically for medical device applications. Designed to safely degrade within the body, these polymers eliminate the need for surgical removal, significantly reducing the risk of long-term complications and enhancing overall patient safety. The polymers’ controlled...

Published: 1/2/2026 | Inventor(s): Kaitlyn Sadtler, Ravi Lokwani

Keywords(s):

Category(s): Application > Medical Devices, Application > Therapeutics, ResearchProducts > Human Cell Lines

Innovative Antibody Conjugates for Targeted Therapy

This advanced technology introduces innovative antibody conjugates that redefine the possibilities of targeted therapy. By coupling therapeutic agents to engineered antibodies with highly specific binding sites, these conjugates deliver treatments directly to diseased cells while sparing healthy tissues. The result is a powerful increase in treatment...

Published: 1/2/2026 | Inventor(s): Nicole Morgan, Paniz Rezvan Sangsari, Parinaz Fathi, Kaitlyn Sadtler

Keywords(s):

Category(s): Application > Therapeutics, Application > Diagnostics, TherapeuticArea > Oncology, TherapeuticArea > Immunology

Innovative Antibody Conjugates for Targeted Therapeutics

This cutting-edge technology leverages innovative conjugated antibodies to transform the way diseases are treated. By engineering antibodies to deliver therapeutic agents directly to specific cells, this approach offers a powerful combination of precision, potency, and safety. Unlike traditional therapies that often impact healthy tissues and cause...

Published: 1/2/2026 | Inventor(s): Kaitlyn Sadtler, Devon Hartigan, Katharina Maisel

Keywords(s):

Category(s): Application > Therapeutics, Application > Diagnostics, TherapeuticArea > Oncology, TherapeuticArea > Immunology

Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapy

Summary: The National Cancer Institute (NCI) seeks capable licensees interested in commercializing T cell receptor (TCR)-engineered T cells expressing murine/human hybrid receptors. Description of Technology: TCR-T therapies, particularly those targeting patient-specific neoantigens, remain a promising approach to the treatment metastatic cancers....

Published: 8/25/2025 | Inventor(s): Steven Feldman, Steven Rosenberg, Drew Deniger

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Chimeric Antigen Receptors Targeting the Gamma Delta (γδ) T-Cell Receptor

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a set of Chimeric Antigen Receptors (CARs) that target the γδ T-Cell Receptor. Description of Technology: T cells express two main types of receptors based on the proteins that make up the T-cell receptor (TCR) heterodimers: ab (alpha...

Published: 8/25/2025 | Inventor(s): James Kochenderfer, Lauren Cutmore

Keywords(s):

Category(s): TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients with Chronic Viral Infection(s)

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for development of papilloma-infiltrating lymphocytes (PIL) as treatment for patients with chronic human papillomavirus (HPV) 6 or 11 infections. Description of Technology: Recurrent Respiratory Papillomatosis (RRP) and anogenital condyloma are caused...

Published: 8/21/2025 | Inventor(s): Scott Norberg, Clint Allen, Zulmarie Franco, Ke Bai

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

1 2 3 4 5 6 7 8 9 10 ...